Navigation Links
CSL Limited Signs Commercial License Agreement with Selexis SA
Date:7/26/2011

GENEVA, July 26, 2011 /PRNewswire/ -- Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited (ASX:CSL Australia) has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.

"We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform," said Dr. Igor Fisch, CEO, Selexis SA. "This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."  

Terms of the agreement were not disclosed.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

About CSL Limited

Headquartered in Melbourne, Australia, with major facilities in Germany, Switzerland and the U.S., CSL has more than 10,000 employees working in 27 countries. The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years of experience in the development and manufacture of vaccines and plasma protein biotherapies. In fiscal 2010, the company produced revenues of approximately A$4.5 billion.

For more information visit http://www.csl.com.au  

Media Contact: Robert Meister, (602) 953-1716


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. World TB Day Donation Campaign Increases Access to Improved TB Tests in Resource-Limited Settings
2. Healthzone Limited Engages The Trout Group for Investor Relations Services
3. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
4. New President and CEO appointed at Ocean Nutrition Canada Limited
5. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
6. The Independent Committee of the Board of Directors of Tongjitang Appoints Morgan Stanley Asia Limited as Its Financial Advisor
7. Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited
8. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
9. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
10. Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
11. Optimization and Scale-up of a Hydrodynamically Limited Anti-Solvent Crystallization Process: From Lab to Plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... ... 2017 , ... The University of Connecticut, in partnership with ... startups through the UConn Innovation Fund. The $1.5 million UConn Innovation Fund was ... , The UConn Innovation Fund provides investments of up to $100,000 to companies ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology ... of emerging technology-based businesses, recently earned a $77,518 grant from the Rural Maryland ... in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI is a ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... USDM ... for the life sciences and healthcare industries, is pleased to announce Holger Braemer ... established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer is an ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):